ArticleNPJ breast cancer2021
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Article in NPJ breast cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06087120 (Investigate the Prognostic and Predictive Value of Circulating Tumor DNA), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.
Who cites it
39 citing papers in PubMed, 51 citations in OpenAlex.
- Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Assessment of MRD and Longitudinal Monitoring of Post-Surgery Biliary Tract Cancer With a Customized ctDNA Panel.Cancer science · 2026Article
- Emerging technologies for monitoring breast cancer response to neoadjuvant chemotherapy: a systematic scoping review.Breast (Edinburgh, Scotland) · 2026Review
- The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Artificial intelligence-driven multimodal fusion for precision diagnosis and personalized management of breast cancer.Oncology reviews · 2026Review
- A dynamic nomogram for predicting axillary pathological complete response and its prognostic value in HER2-positive breast cancer.Frontiers in oncology · 2026Article
- Article
- Artificial Intelligence Measured Tumor Burden and Pre-Treatment Circulating Tumor DNA in Human Papilloma Virus-Associated Oropharynx Cancer.Head & neck · 2025Article
- Detection and Monitoring of Breast Cancer Local Recurrence Via Circulating Tumor DNA Minimal Residual Disease Assay.JCO precision oncology · 2025Article
- Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer.Translational lung cancer research · 2025Review
- Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy.Nature communications · 2025Article
- Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.Seminars in immunopathology · 2025Review
- The impact of radiogenomics on breast cancer.American journal of cancer research · 2025Review
- Dynamic ultrasound-based modeling predictive of response to neoadjuvant chemotherapy in patients with early breast cancer.Scientific reports · 2024Article
- Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors.Molecular oncology · 2024Article
- Review
- Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes.Cancers · 2024Review
- Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer.NPJ breast cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
We investigated whether serial measurements of circulating tumor DNA (ctDNA) and functional tumor volume (FTV) by magnetic resonance imaging (MRI) can be combined to improve prediction of pathologic complete response (pCR) and estimation of recurrence risk in early breast cancer patients treated with neoadjuvant chemotherapy (NAC). We examined correlations between ctDNA and FTV, evaluated the additive value of ctDNA to FTV-based predictors of pCR using area under the curve (AUC) analysis, and analyzed the impact of FTV and ctDNA on distant recurrence-free survival (DRFS) using Cox regressions. The levels of ctDNA (mean tumor molecules/mL plasma) were significantly correlated with FTV at all time points (p < 0.05). Median FTV in ctDNA-positive patients was significantly higher compared to those who were ctDNA-negative (p < 0.05). FTV and ctDNA trajectories in individual patients showed a general decrease during NAC. Exploratory analysis showed that adding ctDNA information early during treatment to FTV-based predictors resulted in numerical but not statistically significant improvements in performance for pCR prediction (e.g., AUC 0.59 vs. 0.69, p = 0.25). In contrast, ctDNA-positivity after NAC provided significant additive value to FTV in identifying patients with increased risk of metastatic recurrence and death (p = 0.004). In this pilot study, we demonstrate that ctDNA and FTV were correlated measures of tumor burden. Our preliminary findings based on a limited cohort suggest that ctDNA at surgery improves FTV as a predictor of metastatic recurrence and death. Validation in larger studies is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.